On Monday, 4 October, PSYCH released The Psychedelics as Medicine Report: Third Edition.
The 200+ page report examines the burgeoning psychedelic healthcare industry, with proprietary market insights and intelligence empowering investors to identify commercial opportunities.
Complimentary download
The city council voted unanimously to decriminalise the cultivation and consumption of psilocybin, mescaline and ibogaine.
Read More
On 7 October the PSYCH Investor Summit will host engaging panel discussions and investor focused company presentations.
Read MoreMydecine to supply psilocybin for government-funded smoking cessation study.
Creso Pharma subsidiary starts testing psilocybin for its Phase II trial.
Awakn closes acquisition of Norwegian ketamine clinic.
Braxia Scientific shares results on ketamine’s efficacy as an antidepressant.
Delic Labs applies for licence to expand research beyond psilocybin.
MindMed partners with employee-benefits provider Sphere Health.
Delic partners with Paradigm for ketamine testing solution.
Elon Musk acknowledges therapeutic potential of psychedelic drugs.
Cybin appoints new Chief Medical Officer for Europe and Head of Research and Development.
Diamond Therapeutics appoints Dr Torsten Passie to Scientific Advisory Board.
Bruce Linton steps down from MindMed’s board of directors.
SPEAKERS
EVENT STARTS – 10.00am EST / 3.00pm BST
KEYNOTE SPEECH
US Government issues first grant for psychedelic research in over 50 years.
The psychedelics industry could offer a whole new approach to work.
Psychedelic therapy, a roadmap for wider acceptance and utilisation.
Psychedelics: Psychiatry of the future.
BBC Science Focus: Psilocybin makes music more emotional to the brain.
Assessing the safety profile and drug-drug interactions of ketamine, MDMA and psilocybin.
Can psychedelic drugs treat physical pain?
Australia’s medicines regulator recognises value of psychedelic medicines.
California could decriminalise psychedelic medicines in 2022.